Nafamostat mesilate for blood thinning in ECMO patients
Part of Heart & circulation clinical trials.
This trial tests a medicine called nafamostat mesilate to prevent blood clots in patients who need ECMO (a machine that helps your heart and lungs) after heart surgery. It may offer a safer way to thin the blood compared to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You must have ECMO (a heart-lung support machine) after cardiac surgery.
- Your medical team decides you need blood-thinning medication.
- You are able to sign a consent form after understanding the study.
- You do not have any condition that causes active bleeding or makes it unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if bivalirudin is a safe and effective blood thinner for people on ECMO, a machine that helps your heart and lungs. You may be eligible if you need this therapy and have no past reactions to similar medicines.
This trial studies whether people on a breathing machine called VV-ECMO can be managed without routine blood thinners, to reduce bleeding risk. It is meant for adults with severe lung failure (ARDS) and checks that it is safe for you to avoid anticoagulation.
This Phase 2 trial compares two blood-thinning medicines—bivalirudin and heparin—in people on ECMO (a machine that supports breathing and/or circulation). It aims to see which medicine works better and is safer while you are connected to the ECMO circuit.
This study looks at how platelets (the cells that help clot blood) behave in patients on a lung-support machine called ECMO. By taking blood samples, researchers hope to better understand clotting issues that can occur during ECMO support.
This trial tests a way to manage blood clotting in patients on ECMO (a machine that helps breathe for very sick patients). It uses a drug called Nafamostat with a lower dose of standard blood thinners, which may reduce bleeding risks.
This trial studies a safe, backup ECMO machine for people with very weak hearts or complex blockages who need high-risk stenting. It helps keep your blood pumping if your heart struggles during the procedure.
Hear when a new Extracorporeal Membrane Oxygenation Complication trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.